On Wednesday, 14 May 2025, Merck & Co. (NYSE:MRK) presented at the BofA Securities 2025 Healthcare Conference. The discussion focused on strategic developments, highlighting both opportunities and challenges. Key areas included the impact of policy changes, particularly the Most Favored Nation proposal, and the future trajectory of Keytruda, Merck's flagship oncology product.